Descriptive only

Vomiting

Polycystic ovary syndrome

longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)

Randomized trials

Treatments

226

Participants

Events

In plain language

No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 3 trials. The trial data below are shown as reported.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.

Baseline effect modifiers and prognostic factors per trial
Trial	Sex (percent female) effect modifier, prognostic factor; 3 of 3
SAXAPCOS S000534	100
LIPT S000948	100
S003101 S003101	100

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

FlagRisk of bias, funding: confounded with design: industry 1, mixed 2
NoteOutcome assessment, time point: selected time points span 26 to 36 weeks
NoteOutcome assessment, analysis set: mixed: other 1, safety 2
NoteData handling, input conversions: nonserious_only 2

Comparability items per trial
Trial	time weeks	analysis set	definition	instrument	adjudicated	proportion method	intercurrent events (discontinuation)	intercurrent events (rescue)	blinding	funding	start year	Eligibility
SAXAPCOS	36	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2018	premenopausal women 18 to 45 years; PCOS by modified NIH 1990; BMI 30 or more; no diabetes
LIPT	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	mixed	2014	Rotterdam PCOS; BMI over 25 or insulin resistance; non hormonal contraception; no diabetes or CVD
S003101	26	other	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	mixed	2014	premenopausal women 18 or older; Rotterdam PCOS; BMI 25 or more and/or C-peptide above 0.6 nmol/L; no diabetes

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Events / N	Flags	Source
SAXAPCOS	A1	LIRA_SC_3p0MG_QD	36	arm, events	5 / 55		R0022023:Table 4
SAXAPCOS	A2	PLACEBO	36	arm, events	0 / 27		R0022023:Table 4
LIPT	A1	LIRA_SC_1p8MG_QD	26	arm, events	5 / 48	nonserious_only	registry:adverse_events
LIPT	A2	PLACEBO	26	arm, events	0 / 24	nonserious_only	registry:adverse_events
S003101	A1	LIRA_SC_1p8MG_QD	26	arm, events	5 / 48		R0025661:Table 2
S003101	A2	PLACEBO	26	arm, events	0 / 24		R0025661:Table 2

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab